An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

Assessment of cell free DNA (cfDNA) and RNA (cfRNA), circulating tumor cells (CTC) and
extracellular vesicles (EV) in blood or other bodily fluids can enable early cancer detection …

Lung cancer is the predominant cause of cancer-related mortality in the world. The majority
of patients present with locally advanced or metastatic non-small-cell lung cancer (NSCLC) …

Breast cancer management has witnessed significant advancements, especially in the
diagnosis and treatment response monitoring through the implementation of imaging …

Treatments for cancer patients are becoming increasingly complex, and there is a growing
desire from clinicians and patients for biomarkers that can account for this complexity to …

The study of cell-free DNA (cfDNA) is often challenging due to genomic DNA contamination,
low concentration, and high fragmentation. Therefore, it is important to optimize pre …

Blood contains multiple analytes that can be used as liquid biopsy to analyze cancer.
Mutations have been detected in DNA associated with small extracellular vesicles (sEVs) …

Liquid biopsy is a new diagnostic concept to investigate the molecular features of solid
tumors by blood, saliva, urine, and any other body fluids which show a source of potential …

The success of personalized medicine depends on the discovery of biomarkers that allow
oncologists to identify patients that will benefit from a particular targeted drug. Molecular …

Recently, liquid biopsy, as a promising approach was introduced for the analysis of different
tumor-derived circulating markers including tumor DNA and cell free DNA (ct/cfDNA) …